An 11-year nationwide registry-linkage study of opioid maintenance treatment in pregnancy in Norway
DOI:
https://doi.org/10.5324/nje.v29i1-2.4047Sammendrag
Aim: We aimed to describe opioid maintenance treatment (OMT) to pregnant women in Norway and study the
background characteristics of the pregnant women compared to the general population of pregnant women and
to a previous clinical cohort study of OMT in pregnancy.
Methods: Population-based cohort study with linked data from the Norwegian Medical Birth Registry, the
Norwegian Prescription Database, the Norwegian Patient Registry, and Statistics Norway. The study population
consisted of women giving birth between 2005-2015 in Norway. We defined OMT pregnancies as pregnancies
where the woman was dispensed OMT medications (methadone, buprenorphine, or buprenorphine/
naloxone) at least once during pregnancy.
Results: The study population consisted of 420,808 women with 645,440 pregnancies ending in a live birth in
Norway in 2005-2015 (the general pregnant population). Of these, 261 women (0.6‰) had altogether 306
OMT pregnancies. The mean number of pregnancies was 28 OMT pregnancies per year and quite stable during
the study period. Women with OMT pregnancies were older, smoked tobacco more frequently, had lower
education, and fewer of them had a partner, compared to the general population of pregnant women. In most
pregnancies, the women were treated with buprenorphine (n=183 (59.8%)), while in 120 (39.2%) pregnancies,
the woman received methadone. From 2008, buprenorphine replaced methadone as the most frequently used
drug. In only 38 (12.4%) pregnancies, OMT treatment was initiated in pregnancy. In 201 (66%) pregnancies,
the woman used OMT medications in all trimesters. For these women, the mean amount of dispensed drug was
3.4 DDD/day (85 mg/day) in pregnancy for methadone and 1.9 DDD/day (15.2 mg/day) for buprenorphine.
Conclusion: The number of OMT pregnancies per year has been low and stable in the period 2005-2015.
Following Norwegian recommendations, there has been a shift from treatment with methadone towards
buprenorphine. The women receiving OMT during pregnancy had more risk factors for adverse outcomes than
the general pregnant population but were quite similar to the previous clinical cohort.
Downloads
Nedlastinger
Publisert
Hvordan referere
Utgave
Seksjon
Lisens
Opphavsrett 2021 Ingvild Odsbu, Milada Mahic
Dette verket er lisensiert under en Creative Commons Attribution 4.0 International Lisens.
Norsk Epidemiologi licenses all content of the journal under a Creative Commons Attribution (CC-BY) licence. This means, among other things, that anyone is free to copy and distribute the content, as long as they give proper credit to the author(s) and the journal. For further information, see Creative Commons website for human readable or lawyer readable versions.
Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
